RecruitingPhase 3NCT07805954

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Sponsor

Revolution Medicines, Inc.

Enrollment

400 participants

Start Date

Aug 28, 2026

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic Pancreatic Adenocarcinoma PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Metastatic Pancreatic Adenosquamous Carcinoma

Summary

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called daraxonrasib, a drug called gemcitabine, and others for people with pdac, pdac - pancreatic ductal adenocarcinoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdaraxonrasib

oral tablets

DRUGgemcitabine

intravenous (IV) infusion

DRUGnab-paclitaxel

IV infusion

DRUGzoldonrasib

oral tablets

Locations(1)

Moffitt Cancer Center

Tampa, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07805954

Related Trials

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT074508593 locations

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT07435038

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT0756215231 locations

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

NCT0721771715 locations

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334454 locations